About Ionis Pharmaceuticals
Ionis Pharmaceuticals (IONS) focuses on discovering, developing, and commercializing RNA-targeted therapies. Ionis Pharmaceuticals stock increased ~0.7% to its closing price of $51.73 on September 27 from its September 26 closing price of $51.39. The chart below compares the changes in analysts’ recommendations for Ionis Pharmaceuticals since January.
Ionis Pharmaceuticals’ performance
Ionis Pharmaceuticals’ (IONS) stock price was nearly flat in September and has risen 14.5% over the last month. Ionis Pharmaceuticals reported a 0.3% decrease in its price over the last 12 months and a 2.8% increase in its year-to-date price.
Analysts’ estimates show that its stock could increase ~8.7% over the next 12 months. Wall Street recommendations show a 12-month target price of $56.25 per share, compared to its September 27 price of $51.73 per share.
Thirteen analysts tracked Ionis Pharmaceuticals (IONS) on September 28. The stock received one “strong buy” rating, three “buy” ratings, seven “hold” ratings, and two “sell” ratings. The consensus rating for Ionis Pharmaceuticals stands at 2.77, which represents a “hold” recommendation.
The Invesco Dynamic Biotechnology & Genome ETF (PBE) holds 3.1% of its portfolio in Ionis Pharmaceuticals (IONS), 5.3% in Amgen (AMGN), 5.1% in Biogen (BIIB), and 4.9% in Regeneron Pharmaceuticals (REGN).